A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

Exclusion Criteria

• •Known history of factor IX inhibitors
• •Inhibitors to factor IX (above or equal to 0.6 BU) at screening measured by the Nijmegen modified Bethesda method
• •Immunocompromised (CD4+ T cells below or equal to 200/μL)
• •Known congenital or acquired coagulation disorders other than haemophilia B
• •Body mass index above 35 kg/m\^²